Variable name;level;Overall;Yes;No;p;test
;n;1357;262;1095;;
Age;[0 -30);95;63 (66.3);32 (33.7);<0.001;
;[30 -35);246;119 (48.4);127 (51.6);;
;[35 -40);460;76 (16.5);384 (83.5);;
;40+;554;4 (0.7);550 (99.3);;
Number of children;0;373;177 (47.5);196 (52.5);<0.001;
;1;279;53 (19);226 (81);;
;More than 1;705;32 (4.5);673 (95.5);;
BMI;<18.5;79;16 (20.3);63 (79.7);0.035;
;25-29.9;257;46 (17.9);211 (82.1);;
;>=30;107;12 (11.2);95 (88.8);;
;18.5-24.9;807;181 (22.4);626 (77.6);;
Treatment center;Curie Paris;818;168 (20.5);650 (79.5);0.184;
;Curie St Cloud;538;94 (17.5);444 (82.5);;
Hereditary predisposition;No;547;159 (29.1);388 (70.9);0.441;
;Yes;140;46 (32.9);94 (67.1);;
Inflammatory BC;No;1338;260 (19.4);1078 (80.6);0.557;
;Yes;18;2 (11.1);16 (88.9);;
Clinical Tumor size (mm);;30.3 (21.7);32.0 (20.2);29.9 (22.1);0.167;
Clinical N stage (TNM);N0;854;165 (19.3);689 (80.7);0.476;
;N1;482;96 (19.9);386 (80.1);;
;N2;7;0 (0);7 (100);;
;N3;3;0 (0);3 (100);;
SBR grade;Grade I;58;11 (19);47 (81);0.647;
;Grade II;528;96 (18.2);432 (81.8);;
;Grade III;760;154 (20.3);606 (79.7);;
Histological type;Lobular;54;6 (11.1);48 (88.9);0.295;
;NST;1265;249 (19.7);1016 (80.3);;
;Others;36;7 (19.4);29 (80.6);;
Neoajuvant chemotherapy;No;744;118 (15.9);626 (84.1);<0.001;
;Yes;612;144 (23.5);468 (76.5);;
Chemotherapy setting;Adjuvant;744;118 (15.9);626 (84.1);0.001;
;Chemotherapy without surgery;1;0 (0);1 (100);;
;NAC;611;144 (23.6);467 (76.4);;
Fertility preservation discussion;No;909;3 (0.3);906 (99.7);<0.001;
;Yes;447;259 (57.9);188 (42.1);;
